Albert J. Wong, M.D.
Publications
- EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene. 2013; (21): 2670-81
- A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors. Oncogene. 2012; (24): 2953-67
- Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. Cancer Res. 2012; (10): 2657-71
- Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol. 2012; (3): 395-402
- Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Rev Vaccines. 2012; (2): 133-44
- Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A. 2011; (11): 4453-8
- The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene. 2011; (2): 234-44
- Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol. 2010: 72
- Measuring the constitutive activation of c-Jun N-terminal kinase isoforms. Methods Enzymol. 2010: 531-48
- Pineal parenchymal tumor of intermediate differentiation: clinicopathological report and analysis of epidermal growth factor receptor variant III expression. Neurosurgery. 2010; (5): 963-8; discussion 968
- Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010; (6): 741-54
- The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. Neurosurg Clin N Am. 2010; (1): 87-93
- Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation. J Biol Chem. 2008; (50): 34935-45
- EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines. 2008; (7): 977-85
- The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. J Biol Chem. 2007; (11): 7758-69
- Beta1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment. Cancer Res. 2006; (1): 331-42
- c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res. 2006; (20): 10024-31
- Host adaptor proteins Gab1 and CrkII promote InlB-dependent entry of Listeria monocytogenes. Cell Microbiol. 2005; (3): 443-57
- Identification of a specific domain responsible for JNK2alpha2 autophosphorylation. J Biol Chem. 2005; (11): 9913-20
- Alterations in the expression of androgen receptor, wild type-epidermal growth factor receptor and a mutant epidermal growth factor receptor in human prostate cancer. Afr J Med Med Sci. 2004; (3): 245-53
- Role of the Grb2-associated binder 1/SHP-2 interaction in cell growth and transformation. Cancer Res. 2004; (6): 2007-15
- Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res. 2003; (1): 250-5
- Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci. 2003; (1): 50-6
- Gab1 is an integrator of cell death versus cell survival signals in oxidative stress. Mol Cell Biol. 2003; (13): 4471-84
- Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer. 2003; (2): 273-80
- Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene. 2002; (33): 5038-46
- Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol. 2002; (2): 441-7
- Further characterization of storage-related alterations in immunoreactivity of archival tissue sections and its implications for collaborative multicenter immunohistochemical studies. Appl Immunohistochem Mol Morphol. 2001; (3): 261-6
- Grb-2-associated binder-1 is involved in insulin-induced egr-1 gene expression through its phosphatidylinositol 3'-kinase binding site. DNA Cell Biol. 2001; (4): 223-9
- New approaches to the molecular biology, classification, and therapy of nervous system tumors: a workshop of the National Institutes of Health Pathology B study section. Am J Pathol. 2001; (5): 1971-4
- Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol. 2001; (5): 755-62
- The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase. J Biol Chem. 2001; (15): 12257-65
- Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 2000; (11): 3081-7
- Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 2000; (1): 186-94
- The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000; (22): 8513-25
- 1998 Neurotumor Club. March 30, 1998, New Orleans, La. Neuro Oncol. 1999; (1): 30-2
- A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis. J Biol Chem. 1999; (44): 31719-26
- Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res. 1999; (19): 4973-83
- Gab1 mediates neurite outgrowth, DNA synthesis, and survival in PC12 cells. J Biol Chem. 1999; (52): 37307-14
- The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 1999; (3): 1784-99
- Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem. 1998; (5): 2817-22
- Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem. 1998; (1): 200-6
- Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest. 1998; (2): 406-12
- Determination of Gab1 (Grb2-associated binder-1) interaction with insulin receptor-signaling molecules. Mol Endocrinol. 1998; (7): 914-23
- The Gab1 protein is a docking site for multiple proteins involved in signaling by the B cell antigen receptor. J Biol Chem. 1998; (46): 30630-7
- A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 1997; (8): 1419-24
- Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356. J Biol Chem. 1997; (33): 20811-9
- Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1. J Biol Chem. 1997; (32): 20167-72
- Epidermal growth factor receptor stimulation of diacylglycerol kinase. Biochem Biophys Res Commun. 1997; (1): 111-6
- Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. Proc Natl Acad Sci U S A. 1997; (23): 12419-24
- Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem. 1997; (7): 4079-86
- The Nck SH2/SH3 adaptor protein is present in the nucleus and associates with the nuclear protein SAM68. Oncogene. 1997; (2): 223-31
- A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature. 1996; (6565): 560-4
- Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res. 1996; (9): 1997-2002
- Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene. 1996; (1): 85-96
- Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem. 1995; (51): 30562-6
- Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995; (23): 5536-9
- Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995; (14): 3140-8
- Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. 1995; (19): 4375-82
- Polymorphism at codon 36 of the p53 gene. Oncogene. 1994; (1): 327-8
- The molecular biology and molecular genetics of astrocytic neoplasms. Semin Oncol. 1994; (2): 139-48
- Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 1993; (14): 3217-20
- Oncogenes and signal transduction. Hosp Pract (Off Ed). 1993; (7): 128-32, 136-8, 141
- Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992; (7): 2965-9
- Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun. 1991; (3): 1413-20
- Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A. 1990; (11): 4207-11
- Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 1990; (24): 8017-22
- Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. 1988; (8): 2231-8
- Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol. 1988; (3): 191-205
- The GLI-Kruppel family of human genes. Mol Cell Biol. 1988; (8): 3104-13
- Identification of an amplified, highly expressed gene in a human glioma. Science. 1987; (4797): 70-3
- Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987; (19): 6899-903
- Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet Cytogenet. 1987; (1): 165-70
- Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science. 1986; (4762): 461-4
- Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science. 1985; (4693): 1487-90
- Myosin from human erythrocytes. J Biol Chem. 1985; (1): 46-9
- Actin filament stress fibers in vascular endothelial cells in vivo. Science. 1983; (4586): 867-9
- Contractile proteins in endothelial cells. Ann N Y Acad Sci. 1982: 50-60
Help
Trial Administration